Voyager Therapeutics (VYGR) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Voyager Therapeutics (VYGR) overview

Voyager Therapeutics (VYGR) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 40.4m and operating profit of USD -132m; the year-end share price was 3.93 USD and market capitalisation was USD 232m. Voyager Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Voyager Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 196mFY 2025
Share price3.93 USDFY 2025 year end
RevenueUSD 40.4mFY 2025
Operating profitUSD -132mFY 2025
Net earningsUSD -120mFY 2025
Market capitalisationUSD 232mFY 2025 year end

About Voyager Therapeutics

Voyager Therapeutics develops genetic medicines for neurological diseases. Its pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease and other central nervous system conditions. Its TRACER platform discovers adeno-associated virus capsids intended to deliver therapies to the brain. The company advances proprietary drug candidates and partnered programs with collaborators, and develops a non-viral delivery platform for neurological therapeutics.

Generate the Voyager Therapeutics report

Voyager Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Voyager Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Voyager Therapeutics

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.